Clinical safety profile of grepafloxacin

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 395-396

  Lode, H ^a   Vogel, F ^a   Elies, W ^a  

^a MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GREPAFLOXACIN;

BRONCHITIS; CARDIOTOXICITY; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMONIA; SKIN MANIFESTATION; TASTE DISORDER; VERTIGO; VOMITING;

EID: 0032708669     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00137     Document Type: Conference Paper

References (12)

1. 1. HS Sader ME Erwin RN Jones 1992 In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones Eur J Clin Microbiol Infect Dis 11 4 372 81 1327789 10.1007/BF01962081 1:CAS:528:DyaK38XmtVyktLk%3D Sader HS, Erwin ME, Jones RN. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis 1992; 11(4): 372–81
2. 2. Thornsberry C, Ogilvie P, Holley Jr HP. The activity of fluoroquinolones and other antimicrobial agents against community isolates of S. pneumoniae, H. influenzae and M. catarrhalis [abstract E-3]. Proceedings of the 37th Interscience Congress on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1: Toronto, Canada
3. 3. GI Ridgway H Salman MJ Robbins 1997 The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp J Antimicrob Chemother 40 A 31 4 9484871 10.1093/jac/40.suppl_1.31 1:CAS:528:DyaK1cXot1OksQ%3D%3D Ridgway GI, Salman H, Robbins MJ, et al. The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997; 40 Suppl. A: 31–4
4. 4. C Efthymiopoulos SI Bramer A Maroli 1997 Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy subjects Clin Pharmacokinet 33 1 1 8 9433650 10.2165/00003088-199700331-00003 1:CAS:528:DyaK1cXitVKmtg%3D%3D Efthymiopoulos C, Bramer SI, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy subjects. Clin Pharmacokinet 1997; 33 Suppl. 1: 1–8
5. 5. S Chodosh 1998 Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infections Clin Microbiol Infect 4 1 S25 S31 11869247 10.1111/j.1469-0691.1998.tb00686.x 1:CAS:528:DyaK1cXis1WhsL8%3D Chodosh S. Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infections. Clin Microbiol Infect 1998; 4 Suppl. 1: S25–S31
6. 6. P Ball G Tillotson 1995 Tolerability of fluoroquinolone antibiotics Drug Saf 13 6 343 58 8652079 10.2165/00002018-199513060-00004 1:CAS:528:DyaK28XnvFyjsw%3D%3D Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13(6): 343–58
7. 7. Shintani S, Kusunoki A, Hosoki E, et al. Drug interaction of OPC-17116, a new quinolone antibacterial agent, with nonsteroidal anti-inflammatory drugs in experimental animals [abstract 1479]. Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sep 29–Oct 2: Chicago, Illinois
8. 8. K Owen 1998 Comparative grepafloxacin phototoxicity in mouse skin J Antimicrob Chemother 42 2 261 4 9738848 10.1093/jac/42.2.261 1:CAS:528:DyaK1cXls1Kgsrc%3D Owen K. Comparative grepafloxacin phototoxicity in mouse skin. J Antimicrob Chemother 1998; 42(2): 261–4
9. 9. Owen K, Moult AB, Waldron MN. The comparative toxicity of fluoroquinolones in rats [abstract 47.021]. 8th International Congress for Infectious Diseases (ICID); 1998 May 15–18: Boston, USA: 127-8
10. 10. H Lode F Vogel W Elies 1999 Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance Clin Ther 21 61 74 10090425 10.1016/S0149-2918(00)88268-5 1:CAS:528:DyaK1MXhslCrt7o%3D Lode H, Vogel F, Elies W. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Clin Ther 1999; 21: 61–74
11. 11. Data on file, Glaxo Wellcome
12. 12. SJ Tschida DR Guay LL Hoey 1996 QTc prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: aprospective evaluation and review of the literature Pharmacotherapy 16 4 663 74 8840374 1:CAS:528:DyaK2sXitFaksro%3D Tschida SJ, Guay DR, Hoey LL, et al. QTc prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: aprospective evaluation and review of the literature. Pharmacotherapy 1996; 16(4): 663–74